Related Experiment Video
Updated: Aug 13, 2026
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Integrating Network Pharmacology, Bioinformatics, Transcriptome Sequencing, And Experiments To Explore Mechanisms of
Jing Wang1, Li Zhang2, Ying Yu2
1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, China.
Introduction/Objective:
Breast cancer is one of the most common malignant tumors in women worldwide, and Danggui Shaoyao San (DGSY San) is commonly used in the clinical treatment of breast cancer.
Methods:
This study integrates UHPLC-QE-MS/MS, network pharmacology, transcriptomics, and in vitro experiments to explore the mechanism of DGSY San's anti-breast cancer effects.
Results:
Mass spectrometry identified 70 active ingredients. Network analysis predicted that it regulates apoptosis and proliferation through the MAPK pathway. in vitro experiments showed that DGSY San inhibited the proliferation, migration, and invasion of MCF-7 cells in a concentration-dependent manner and induced G2-phase arrest and apoptosis. Transcriptome sequencing and comprehensive analyses of network pharmacology and clinical databases simultaneously confirmed enrichment of the MAPK pathway. Western blot confirmed that it downregulated p-p38 and p-ERK phosphorylation and promoted the expression of apoptosis-related proteins.
Discussion:
The results indicate that DGSY San inhibits breast cancer proliferation and induces apoptosis through the MAPK pathway.
Conclusion:
This study developed a multidimensional, integrated analysis model of "components-transcriptome-clinical data" to systematically elucidate the mechanisms underlying TCM prescriptions.
